Rezolute to Participate in Upcoming Investor Conferences
Rezolute (RZLT) management will participate in the Guggenheim 3rd Annual Healthcare Innovation Conference and Jefferies London Healthcare Conference in November 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rezolute (RZLT) management will participate in the Guggenheim 3rd Annual Healthcare Innovation Conference and Jefferies London Healthcare Conference in November 2026.
Fireside chats are scheduled for November 9 at 9:00am ET and November 19 at 1:00pm GMT, respectively. Management will also hold one-on-one investor meetings throughout the conferences.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced that management will participate in the following investor conferences:
Event: Guggenheim 3rd Annual Healthcare Innovation Conference
Date: November 9-11, 2026
Fireside Date/Time: Monday, November 9th at 9:00am ET
Event: Jefferies London Healthcare Conference
Date: November 16-19, 2026
Fireside Date/Time: Thursday, November 19th at 1:00pm GMT
Management will be participating in one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their Guggenheim and Jefferies representatives.
About Rezolute, Inc.
Rezolute is a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI. For more information, visit www.rezolutebio.com.
Contacts:
Christen Baglaneas
Rezolute, Inc.
1411 Broadway, 16th Floor
New York, NY 10018
cbaglaneas@rezolutebio.com
508-272-6717
Carrie McKim
Rezolute, Inc.
1411 Broadway, 16th Floor
New York, NY 10018
cmckim@rezolutebio.com
336-608-9706
